Genmab — Oktober 2023
-
Godmorgen
-
Hvad er der lige pludselig galt med de danske aktier? https://www.proinvestor.com/boards/115875
-
Ja, jeg tror absolut også på at ETF-udsalg af danske aktier har været medvirkende til Genmabs kursderoute: PH: "Fra januar 2023 og til og med august (de nyeste tal, som er offentliggjort) har udlandet solgte danske aktier for næsten 17 mia. Jeg er ret overbevist om, at når vi får september tallene vil den ensidige salgstrafik være fortsat."
-
Shortpositioner på danske aktier https://www.proinvestor.com/boards/115878
-
Takeda Provides Update on EXKIVITY
(mobocertinib) ; it will be working with the FDA towards a voluntary withdrawal of EXKIVITY (mobocertinib) in the U.S. for adult patients with epidermal growth factor receptor (EGFR) Exon20 insertion mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC)
https://www.businesswire.com/news/home/20231002169446/en/Takeda-Provides-Update-on-EXKIVITY-mobocertinib -
-
The end of Exkivity is another win for Rybrevant https://www.oncologypipeline.com/apexonco/end-exkivity-another-win-rybrevant
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind